Evaluation of intra- and extracellular activity of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.

Summary, in English

We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis. The MIC distribution of SXT was 0.125/2.4-2/38 mg/L for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for H37Rv was 76 mg/L. In an exploratory analysis using fAUC0-24h/MIC ≥25 as a potential target, the cumulative fraction response was ≥90% at doses ≥2400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.

• Author: L Davies Forsman; T Schön; U S H Simonsson; J Bruchfeld; M Larsson; P Juréen; Erik Sturegård; C G Giske; K Angeby
• Department/s: Clinical Microbiology, Malmö
• Publishing year: 2014
• Language: English
• Pages: 7557-7559
• Publication/Series: Antimicrobial Agents and Chemotherapy
• Volume: 58
• Issue: 12
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25246405?dopt=Abstract; http://dx.doi.org/10.1128/AAC.02995-14
• Document type: Journal article
• Publisher: American Society for Microbiology
• Topic: Microbiology in the medical area
• Status: Published
• Research group: Clinical Microbiology, Malmö
• ISBN/ISSN/Other: ISSN: 1098-6596